DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

PFE·Pfizer Inc.

$.
-. (-.%)
After Hours
High
$24.41
Open
$24.35
Market Cap
137.76B
52W High
$28.75
Low
$24.09
P. Close
$24.18
P/E
18.39
52W Low
$23.11
Fwd P/E
8.53
DailyIQ Est.
$29.18
Technical Score (1D)
27
SELL
News Sentiment
81
BULLISH
Pfizer’s latest pipeline update reveals the company has acquired a monthly‑dosed GLP‑1 weight‑loss candidate, Berobenatide, which could give it a convenience edge over competitors’ weekly injections and daily pills, potentially improving patient adherence. This development could shift the competitive dynamics in the rapidly growing obesity drug market, as a monthly regimen may attract prescribers and patients seeking simpler therapy, and the company’s pricing strategy will be closely monitored. Traders should watch for regulatory filing dates and early clinical data releases, which could confirm the drug’s efficacy and safety profile and influence the company’s near‑term revenue outlook. A Bank of America research note, issued just over a day ago, trimmed its price objective for Pfizer from $27 to $26 while maintaining a neutral rating, reflecting a modest downside view on the firm’s near‑term earnings prospects. The downgrade signals that analysts are weighing the uncertainty around the GLP‑1 program against the company’s broader pipeline, and it may affect short‑term investor sentiment. In parallel, the failure of AstraZeneca’s phase III ATTR‑CM trial has lifted attention on Pfizer’s own ATTR‑CM therapy, potentially increasing its market share and pricing power in this rare cardiomyopathy segment. The company’s dividend yield remains attractive, and it is highlighted as a defensive play amid market volatility, suggesting that income‑seeking investors may view it as a stable allocation. FDA approval of the PADCEV® plus Keytruda® combination for muscle‑invasive bladder cancer, announced 14.5 hours ago, establishes a first platinum‑free perioperative treatment and could shift the standard of care, driving adoption and sales growth for both firms. Going forward, traders should monitor real‑world uptake data, payer coverage decisions, and any updates on the GLP‑1 candidate’s regulatory status, as these factors will shape Pfizer’s short‑term earnings trajectory and valuation.
Earnings Summary
Pfizer, a global biopharmaceutical leader, develops and markets medicines and vaccines across cardiovascular, infectious disease, oncology, and rare disease segments, leveraging collaborations with Bristol‑Myers Squibb and BioNTech. In the most recent reporting cycle, the company posted EPS of $0.75 in Q1 2026 and $0.78 in Q2 2026 (forecast $0.6758), both surpassing analyst expectations, while revenue rose to $14.451 billion from $13.653 billion in Q2 2025, marking a 5.9 % increase versus the prior quarter and a 1.8 % rise versus Q4 2025’s $17.557 billion; the firm has consistently beat estimates in every quarter since Q4 2024, with six consecutive EPS beats. Historically, Pfizer’s revenue trajectory has been volatile—down in Q1 2025 after a pandemic‑driven peak, then rebounding through Q3 2025, only to dip again in Q1 2026—yet EPS growth has remained positive, reflecting resilient profitability amid shifting product mix. Recent news highlights a U.S. appeals court ruling that curtailed a key oncology revenue stream, prompting speculation about licensing or accelerated development to offset the loss, alongside a 9‑hour ruling that could raise litigation costs; the firm’s 8 % stake in a GLP‑1 obesity ETF signals potential upside if its obesity pipeline gains traction, while the FDA approval of IBRANCE adds a new revenue source. Investors should watch for settlement announcements or counter‑claims that clarify the financial impact of the patent loss, guidance on IBRANCE sales, and any cost‑control initiatives that could mitigate margin pressure, as these factors will shape the next earnings cycle.

EPS

EstBeatMiss
$0.52$0.63$0.75$0.86$0.97Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.68 - -
Q1'26$0.72$0.75+3.9%
Q4'25$0.58$0.66+14.3%
Q3'25$0.63$0.87+37.4%
Q2'25$0.57$0.78+35.9%
Q1'25$0.67$0.92+36.5%

Revenue

EstBeatMiss
$13.1B$14.4B$15.6B$16.9B$18.1BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$14.6B - -
Q1'26$13.8B$14.5B+4.7%
Q4'25$17.1B$17.6B+2.6%
Q3'25 - $16.7B -
Q2'25 - $14.7B -
Q1'25 - $13.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PFE Stock Snapshot

PFE is currently trading at $24.23, giving Pfizer Inc. a market cap of 137.76B and a P/E ratio of 18.4. Today's range spans $24.09–$24.41, with shares opening at $24.35 and moving up $0.05 (0.2%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 81/100.

Over the past year PFE has traded between $23.11 and $28.75 - the current price is +4.8% off the 52-week low and -15.7% from the high. 36 analysts cover the stock with a Hold consensus and a mean 12-month target of $29.02 (range $24.00–$36.00), implying upside of +19.8%.

The options market is expressing concern about PFE - elevated put activity in large-cap Healthcare names with SELL signals (27/100) is common when the technical and sentiment inputs (bullish, 81/100) both deteriorate. Price: $24.23 (in the lower half of its 52-week range). (P/E: 18.4) At 137.76B in capitalization, that hedging activity from institutional holders can become a feedback loop that amplifies the initial selling pressure. Range: $23.11–$28.75.

Analyst coverage for PFE becomes a double-edged factor in a SELL phase: at 137.76B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 27/100 technical reading and bullish sentiment (81/100) at $24.23 (in the lower half of its 52-week range) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $23.11–$28.75 range establishes where that repricing lands.